DCs are able to acquire tumor antigens from the TME and activate CD8+ T cells and CD4+ T cells and maintain antitumor immune responses by cross-presentation via MHC-I molecules or direct antigen presentation via MHC-II molecules. The gene discussed is CD4; the disease is neoplasm.